Our studies provide convincing evidence that nuclear HDAC3 and cytoplasmic CDH1 have independent prognostic value in pancreatic cancer and provide novel targets for prognostic therapeutics. This evidence concerns the gene HDAC3 and familial pancreatic carcinoma.